Trial Profile
A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients With Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2008 Checked against clinicaltrials.gov record, last updated 16 Oct 2008.
- 06 May 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.